BioLytical Laboratories Inc. announced today that its INSTI® HCV Antibody Test has received approval for immediate market entry into the European Union
By providing access to the world’s first one minute HCV test, we are excited to play a role in reducing transmission in Europe to help diagnose and connect individuals to care.”
— Robert Mackie, CEO
With both taking the test and receiving results in real-time, bioLytical’s INSTI® HCV Antibody Test will help connect more people to care. Treatment can cure more than 95% of people with Hepatitis C, but access to diagnosis is still too low. Ending an epidemic starts with testing. That’s why we’ve developed an all-new, one minute solution for HCV antibody testing.
• The test is portable, does not require any additional equipment, and can be performed in a multitude of settings with easy-to-interpret results in real-time
• Test performance in clinical studies demonstrated high accuracy of over 99%
The innovative rapid through-flow technology allows INSTI® to provide accurate test results in real-time, offering medical professionals the ability to test patients easily and flexibly in different locations.
References
https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09515-6
https://pubmed.ncbi.nlm.nih.gov/29427484/#:~:text=The%20availability%20of%20pangenotypic%20direct,8%2D12%20weeks%20of%20treatment.
<
Communications
bioLytical Laboratories Inc.
+1 866-674-6784
[email protected]
Visit us on social media:
LinkedIn
Twitter
Facebook
